Toggle Main Menu Toggle Search

Open Access padlockePrints

The case for complement component 5 as a target in neurodegenerative disease

Lookup NU author(s): Amelia Stennett, Kallie Friston, Professor Claire Harris, Dr Adam WollmanORCiD, Dr Agnieszka Bronowska, Dr Kate HarrisORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.Introduction: Complement-based drug discovery is undergoing a renaissance, empowered by new advances in structural biology, complement biology and drug development. Certain components of the complement pathway, particularly C1q and C3, have been extensively studied in the context of neurodegenerative disease, and established as key therapeutic targets. C5 also has huge therapeutic potential in this arena, with its druggability clearly demonstrated by the success of C5-inhibitor eculizumab. Areas covered: We will discuss the evidence supporting C5 as a target in neurodegenerative disease, along with the current progress in developing different classes of C5 inhibitors and the gaps in knowledge that will help progress in the field. Expert opinion: Validation of C5 as a therapeutic target for neurodegenerative disease would represent a major step forward for complement therapeutics research and has the potential to furnish disease-modifying drugs for millions of patients suffering worldwide. Key hurdles that need to be overcome for this to be achieved are understanding how C5a and C5b should be targeted to bring therapeutic benefit and demonstrating the ability to target C5 without creating vulnerability to infection in patients. This requires greater biological elucidation of its precise role in disease pathogenesis, supported by better chemical/biological tools.

Publication metadata

Author(s): Stennett A, Friston K, Harris CL, Wollman AJM, Bronowska AK, Madden KS

Publication type: Review

Publication status: Published

Journal: Expert Opinion on Therapeutic Targets

Year: 2023

Volume: 258

Print publication date: 05/10/2023

Online publication date: 14/02/2023

Acceptance date: 03/02/2023

ISSN (print): 1472-8222

ISSN (electronic): 1744-7631

Publisher: Taylor and Francis Ltd.


DOI: 10.1080/14728222.2023.2177532

PubMed id: 36786123